KIAA1841_0610010F05Rik Inhibitors

Staurosporine, known for its broad kinase inhibition, targets ATP-binding sites, potentially affecting the protein's involvement in signal transduction. LY294002 disrupts the PI3K pathway, an important modulator of numerous signaling cascades that could be connected to the protein's regulatory role. Rapamycin acts on the mTOR pathway, an essential regulator of protein synthesis, impacting the protein's expression or activity. Cycloheximide, by inhibiting protein synthesis, could alter the overall levels or turnover of the protein within the cell. The proteasome inhibitor MG132 may affect the protein's degradation process, modifying its regulatory influence.

PD98059 and U0126 serve as MEK inhibitors with potential effects on the MAPK/ERK pathway, which could be pivotal in the protein's function. SB203580 and SP600125, which inhibit p38 MAPK and JNK respectively, modify the cell's response to stress and inflammation, likely intersecting with the protein's operational pathways. Wortmannin, another PI3K inhibitor, could similarly disrupt signaling pathways involving the protein if it is linked to phosphatidylinositol signaling. Z-VAD-FMK, by impeding apoptosis through caspase inhibition, may affect cellular processes that the protein is involved in regulating. Alsterpaullone, a cyclin-dependent kinase inhibitor, could impact cell cycle regulation pathways pertinent to the protein's function.